Abstract
Summary
Androgen deprivation therapy (ADT) or orchiectomy is associated with an increased risk of osteoporosis or fracture. In this nationwide database analysis, we found that ADT or orchiectomy increased the risk of fracture in Chinese patients with prostate cancer. However, the magnitude of increase is seemingly not as large as that in Western populations.
Introduction
ADT using gonadotropin-releasing hormone (GnRH) agonists or orchiectomy is associated with an increased risk of osteoporosis or fracture. To investigate the effects of ADT duration or orchiectomy on any type of fracture in Asian patients with prostate cancer, we conducted this retrospective analysis using a nationwide database in Taiwan.
Methods
We included 17,359 subjects who were newly diagnosed with prostate cancer between January 1, 1998, and December 31, 2007. The risk of first fracture was our primary endpoint.
Results
The rates of fracture from 12 months after prostate cancer diagnosis until the last follow-up date were 8.7 % for all patients, 7.1 % for patients who did not receive ADT or orchiectomy, 9.8 % for patients who received ADT, and 14.4 % for patients who received orchiectomy with or without ADT (P < 0.0001). In a Cox proportional hazard analysis, the relative risk of fracture increased steadily with the number of doses of GnRH agonists received during the first year after cancer diagnosis and with dose density. A significant hazard ratio was observed in patients who received at least nine doses within 1 year after diagnosis and in those whose dose density exceeded two doses per year. Age greater than or equal to 65 years was associated with a significantly lower risk of fracture.
Conclusion
ADT or orchiectomy increases the risk of fracture in Chinese patients with prostate cancer. However, the magnitude of this increase is seemingly not as large as that in Western populations.
Similar content being viewed by others
References
Gunderson K, Wang CY, Wang R (2011) Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans. Cancer Epidemiol 35(4):320–327. doi:10.1016/j.canep.2010.11.007
Cancer Registry Annual Report, 2000–2009, Taiwan: Department of Health, the Executive Yuan, Republic of China; 2003–2012
Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, Haggman M, Andersson SO, Spangberg A, Andren O, Palmgren J, Steineck G, Adami HO, Johansson JE (2014) Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370(10):932–942. doi:10.1056/NEJMoa1311593
Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109(Suppl 1):22–29. doi:10.1111/j.1464-410X.2011.10827.x
Labrie F (2004) Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl 25(3):305–313
Denham JW, Steigler A (2013) Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy. Semin Radiat Oncol 23(3):206–214. doi:10.1016/j.semradonc.2013.01.008
Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U (2006) Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 98(1):20–27. doi:10.1111/j.1464-410X.2006.06176.x
Herr HW, O’Sullivan M (2000) Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163(6):1743–1746
Cree M, Soskolne CL, Belseck E, Hornig J, McElhaney JE, Brant R, Suarez-Almazor M (2000) Mortality and institutionalization following hip fracture. J Am Geriatr Soc 48(3):283–288
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164. doi:10.1056/NEJMoa041943
Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR (2014) Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine 45(3):370–381. doi:10.1007/s12020-013-0083-z
Smith MR (2002) Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 60(3 Suppl 1):79–85, discussion 86
Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS (2004) Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 101(3):541–549. doi:10.1002/cncr.20388
Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL (2013) Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int 111(5):745–752. doi:10.1111/j.1464-410X.2012.11758.x
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D’Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M (2014) Prostate cancer, version 2.2014. J Natl Compr Canc Netw: JNCCN 12(5):686–718
Botrel TE, Clark O, dos Reis RB, Pompeo AC, Ferreira U, Sadi MV, Bretas FF (2014) Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol 14:9. doi:10.1186/1471-2490-14-9
Gambert SR, Schultz BM, Hamdy RC (1995) Osteoporosis. Clinical features, prevention, and treatment. Endocrinol Metab Clin N Am 24(2):317–371
Redmond J, Jarjou LM, Zhou B, Prentice A, Schoenmakers I (2014) Ethnic differences in calcium, phosphate and bone metabolism. Proc Nutr Soc 73(2):340–351. doi:10.1017/S0029665114000068
Conde FA, Aronson WJ (2003) Risk factors for male osteoporosis. Urol Oncol 21(5):380–383
Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184(3):918–923
Wang W, Yuasa T, Tsuchiya N, Maita S, Kumazawa T, Inoue T, Saito M, Ma Z, Obara T, Tsuruta H, Satoh S, Habuchi T (2008) Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr-Relat Cancer 15(4):943–952. doi:10.1677/ERC-08-0116
Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T (2010) Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75(5):1131–1137. doi:10.1016/j.urology.2009.10.075
Deng JH, Yang LP, Wang LS, Zhou DF (2004) Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian J Androl 6(1):75–77
Herrera A, Lobo-Escolar A, Mateo J, Gil J, Ibarz E, Gracia L (2012) Male osteoporosis: A review. World J Orthop 3(12):223–234. doi:10.5312/wjo.v3.i12.223
Melton LJ 3rd, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H (2003) Fracture risk following bilateral orchiectomy. J Urol 169(5):1747–1750. doi:10.1097/01.ju.0000059281.67667.97
Townsend MF, Sanders WH, Northway RO, Graham SD Jr (1997) Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79(3):545–550
Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169(6):2008–2012. doi:10.1097/01.ju.0000063820.94994.95
Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745–755. doi:10.1056/NEJMoa0809003
Garcia-Albeniz X, Chan JM, Paciorek AT, Logan RW, Kenfield SA, et al. (2014) Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. ASCO Annual Meeting 2014, May 30-June 3 Chicago, USA. Abstract 5003
Acknowledgments
This work was supported by the research grant from Chang Gung Memorial Hospital (CORPG6D0161).
Author contributions
CDW took part in the conception and design of this study, data acquisition, analysis, and interpretation, and in preparing the draft. YHY took part in data acquisition, analysis, and interpretation and in the statistical analyses. PCC and MFC critically revised the manuscript for important intellectual content. MFC also made the final approval of the submitted version. WCC took part in the conception and design of this study, data acquisition, analysis, and interpretation, and in the final approval of the submitted version. All authors read and approved the final manuscript.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Table 1
(DOC 52 kb)
Supplementary Table 2
(DOC 35 kb)
Rights and permissions
About this article
Cite this article
Wu, CT., Yang, YH., Chen, PC. et al. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. Osteoporos Int 26, 2281–2290 (2015). https://doi.org/10.1007/s00198-015-3135-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-015-3135-9